[Subcutaneous gammaglobulin in common variable immunodeficiency. First experience in Spain]

Area of Science:

• Immunology
• Pharmacology
• Patient Care

Context:

• Primary antibody deficiencies require immunoglobulin replacement therapy.
• Subcutaneous immunoglobulin (SCIg) therapy is an emerging alternative to traditional intravenous immunoglobulin (IVIg).
• Home-based administration offers potential benefits in patient convenience and cost.

Purpose:

• To evaluate the efficacy, safety, quality of life, and cost-effectiveness of weekly home-based SCIg.
• To compare SCIg outcomes with previous IVIg treatment in pediatric patients with common variable immunodeficiency (CVID).

Summary:

• Eleven pediatric CVID patients switched to SCIg, maintaining or reducing dose compared to IVIg.
• SCIg resulted in significantly higher median trough serum IgG levels (850 mg/dl vs. 622 mg/dl) without increasing infection rates (p = 0.212).
• Treatment-related adverse events were mostly mild local reactions, decreasing over time; quality of life improved significantly, with substantial cost savings.

Impact:

• SCIg is a safe, effective, and cost-effective alternative for primary antibody deficiency treatment.
• Home-based SCIg significantly enhances patient quality of life.
• This therapy provides higher serum IgG levels with manageable adverse events, supporting its clinical adoption.